AHR and breast cancer: Brantley et al. [35] provided a rationale for the continued development of AFP464 (Figure 4), which is a precursor of aminoflavone, as an agent to enhance the therapeutic management of breast cancer via dysregulation of the aryl hydrocarbon receptor (AhR) signaling pathway.